Todd Asset Management LLC Has $14.05 Million Stock Holdings in ICON Public Limited (NASDAQ:ICLR)

Todd Asset Management LLC trimmed its position in ICON Public Limited (NASDAQ:ICLR) by 32.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 49,620 shares of the medical research company’s stock after selling 24,339 shares during the quarter. Todd Asset Management LLC’s holdings in ICON Public were worth $14,046,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ICLR. Liontrust Investment Partners LLP increased its position in shares of ICON Public by 108.4% during the third quarter. Liontrust Investment Partners LLP now owns 89,860 shares of the medical research company’s stock worth $22,129,000 after acquiring an additional 46,739 shares in the last quarter. Kornitzer Capital Management Inc. KS lifted its position in shares of ICON Public by 50.7% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 74,820 shares of the medical research company’s stock worth $21,179,000 after buying an additional 25,160 shares in the last quarter. Cullen Investment Group LTD. purchased a new position in ICON Public in the fourth quarter worth $1,620,000. Prime Capital Investment Advisors LLC purchased a new position in ICON Public in the fourth quarter valued at about $416,000. Finally, Amalgamated Bank increased its stake in shares of ICON Public by 15.8% during the 4th quarter. Amalgamated Bank now owns 9,771 shares of the medical research company’s stock worth $2,766,000 after purchasing an additional 1,333 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

ICON Public Price Performance

NASDAQ:ICLR traded up $7.95 during mid-day trading on Friday, hitting $309.02. 567,325 shares of the stock traded hands, compared to its average volume of 557,736. The business’s 50-day moving average price is $319.47 and its 200 day moving average price is $284.79. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.36. The company has a market cap of $25.49 billion, a PE ratio of 37.59, a price-to-earnings-growth ratio of 1.36 and a beta of 1.18. ICON Public Limited has a 12-month low of $181.92 and a 12-month high of $344.77.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported $3.40 EPS for the quarter, beating the consensus estimate of $3.27 by $0.13. The firm had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. On average, analysts expect that ICON Public Limited will post 14.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ICLR shares. Barclays raised their target price on ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Evercore ISI lowered their price objective on ICON Public from $350.00 to $330.00 and set an “outperform” rating on the stock in a research note on Friday, April 26th. Truist Financial upped their price objective on shares of ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Robert W. Baird lifted their target price on shares of ICON Public from $362.00 to $363.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Finally, TD Cowen upped their price target on shares of ICON Public from $343.00 to $349.00 and gave the company a “buy” rating in a research note on Friday, April 26th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $339.44.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.